down arrow

West Pharmaceutical Services, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9553061055
USD
281.77
-2.54 (-0.89%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

276.29284.50

52 Week

187.43348.90
Valuation
Technical
Day's Volume

CASH

244.97 k

Shareholding (Mar 2025)

FII

29.64%

Held by 370 FIIs

DII

26.86%

Held by 54 DIIs

Promoter

0.05%

How big is West Pharmaceutical Services, Inc.?

22-Jun-2025

As of Jun 18, West Pharmaceutical Services, Inc. has a market capitalization of $15.93 billion, with net sales of $2.90 billion and a net profit of $467.20 million over the latest four quarters. The company reported shareholder's funds of $2.68 billion and total assets of $3.64 billion as of Dec 24.

Market Cap: As of Jun 18, West Pharmaceutical Services, Inc. has a market capitalization of 15,928.27 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, West Pharmaceutical Services, Inc. reported net sales of 2,895.60 million and a net profit of 467.20 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2,682.30 million and total assets of 3,643.40 million.

Read More

What does West Pharmaceutical Services, Inc. do?

22-Jun-2025

West Pharmaceutical Services, Inc. manufactures packaging components and delivery systems for injectable drugs, with net sales of $698 million and a market cap of approximately $15.93 billion as of March 2025. Key financial metrics include a P/E ratio of 33.00 and a dividend yield of 0.38%.

Overview: <BR>West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 698 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 90 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 15,928.27 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Dividend Yield: 0.38% <BR>Debt Equity: -0.07 <BR>Return on Equity: 18.49% <BR>Price to Book: 5.94<BR><BR>Contact Details: <BR>Address: 530 HERMAN O WEST DR, EXTON PA: 19341-1147 <BR>Tel: ['1 610 5942900', '1 610 5943318'] <BR>Fax: 1 800 3459800 <BR>Website: https://www.westpharma.com/

Read More

Who are in the management team of West Pharmaceutical Services, Inc.?

22-Jun-2025

As of March 2022, the management team of West Pharmaceutical Services, Inc. includes Patrick Zenner (Independent Chairman), Eric Green (CEO), and several Independent Directors: Mark Buthman, William Feehery, Robert Friel, Thomas Hofmann, and Paula Johnson. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of West Pharmaceutical Services, Inc. includes the following individuals:<BR><BR>- Mr. Patrick Zenner, Independent Chairman of the Board<BR>- Mr. Eric Green, President, Chief Executive Officer, Director<BR>- Mr. Mark Buthman, Independent Director<BR>- Dr. William Feehery, Independent Director<BR>- Mr. Robert Friel, Independent Director<BR>- Mr. Thomas Hofmann, Independent Director<BR>- Dr. Paula Johnson, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is West Pharmaceutical Services, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, but mixed signals suggest caution due to recent underperformance compared to the S&P 500.

As of 3 October 2025, the technical trend for West Pharmaceutical Services, Inc. has changed from mildly bearish to bullish. The weekly MACD is bullish, and the monthly RSI is also bullish, indicating positive momentum. Daily moving averages are bullish, supporting the upward trend. However, the monthly KST is bearish, and the OBV shows a mildly bearish trend on the weekly timeframe, which suggests some caution. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 2.98% and 6.92% respectively, while the S&P 500 returned 1.09% and 4.15%. However, the year-to-date and one-year returns are negative at -18.16% and -9.59%, significantly lagging behind the S&P 500's positive returns of 14.18% and 17.82%. Overall, the current stance is bullish, but with mixed signals that indicate a need for careful monitoring.

Read More

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a valuation grade of "expensive," reflected in its high P/E ratio of 33 and poor long-term performance, despite recent short-term gains.

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43, all of which are higher than many of its peers. For instance, Edwards Lifesciences Corp. has a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a more favorable P/E of 27.42 and an EV to EBITDA of 20.75.<BR><BR>Despite recent short-term performance, where West Pharmaceutical outperformed the S&P 500 with a 1-week return of 3.37% compared to 1.70%, the longer-term outlook is concerning, with a year-to-date return of -17.39% versus the S&P 500's 13.30%. This trend suggests that while the stock may have some short-term momentum, its overall valuation metrics indicate it is not justified at current levels.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 22.89%

 
2

Company has a low Debt to Equity ratio (avg) at times

 
3

Healthy long term growth as Operating profit has grown by an annual rate 12.66%

 
4

Flat results in Jun 25

5

With ROE of 18.49%, it has a fair valuation with a 6.12 Price to Book Value

6

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 18,507 Million (Mid Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.34%

stock-summary
Debt Equity

-0.10

stock-summary
Return on Equity

17.63%

stock-summary
Price to Book

6.32

Revenue and Profits:
Net Sales:
766 Million
(Quarterly Results - Jun 2025)
Net Profit:
132 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.83%
0%
13.83%
6 Months
33.27%
0%
33.27%
1 Year
-12.24%
0%
-12.24%
2 Years
-19.7%
0%
-19.7%
3 Years
15.31%
0%
15.31%
4 Years
-35.1%
0%
-35.1%
5 Years
3.76%
0%
3.76%

West Pharmaceutical Services, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43, all of which are higher than many of its peers. For instance, Edwards Lifesciences Corp. has a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a more favorable P/E of 27.42 and an EV to EBITDA of 20.75. Despite recent short-term performance, where West Pharmaceutical outperformed the S&P 500 with a 1-week return of 3.37% compared to 1.70%, the longer-term outlook is concerning, with a year-to-date return of -17.39% versus the S&P 500's 13.30%. This trend suggests that while the stock may have some short-term momentum, its overall valuation metrics indicate it is not justified...

Read More
West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Metrics

West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Metrics

West Pharmaceutical Services, Inc. has adjusted its valuation metrics, with a P/E ratio of 33 and a price-to-book value of 6.12. The company has shown mixed performance, with recent stock returns outperforming the S&P 500, but a year-to-date decline contrasts with broader market gains.

Read More

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from very expensive to expensive, indicating a shift towards a less favorable valuation outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43. In comparison, peers such as Edwards Lifesciences Corp. have a P/E of 31.17 and Agilent Technologies, Inc. shows a more attractive P/E of 27.42, suggesting that West Pharmaceutical's valuation is not justified relative to its industry counterparts. While West Pharmaceutical has outperformed the S&P 500 over the past week and month, with returns of 3.37% and 5.44% respectively, it has significantly lagged over longer periods, with a year-to-date return of -17.39% compared to the S&P 500's 13.30%. This disparity reinforces the notion that the stock may be overvalued given i...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.71%
EBIT Growth (5y)
12.66%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.98
Tax Ratio
20.26%
Dividend Payout Ratio
12.27%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
32.01%
ROE (avg)
22.89%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
6.12
EV to EBIT
27.17
EV to EBITDA
21.43
EV to Capital Employed
6.48
EV to Sales
5.61
PEG Ratio
NA
Dividend Yield
0.37%
ROCE (Latest)
23.86%
ROE (Latest)
18.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 147 Schemes (43.44%)

Foreign Institutions

Held by 370 Foreign Institutions (29.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 9.74% vs -6.72% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 46.77% vs -30.98% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "766.20",
          "val2": "698.20",
          "chgp": "9.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "199.60",
          "val2": "168.40",
          "chgp": "18.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.10",
          "val2": "-19.70",
          "chgp": "84.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "131.80",
          "val2": "89.80",
          "chgp": "46.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "206.50%",
          "val2": "183.90%",
          "chgp": "2.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1.98% vs 2.27% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.97% vs 1.28% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,892.70",
          "val2": "2,951.10",
          "chgp": "-1.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "750.00",
          "val2": "848.20",
          "chgp": "-11.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.90",
          "val2": "8.80",
          "chgp": "-67.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.00",
          "val2": "-13.80",
          "chgp": "-37.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "492.70",
          "val2": "593.40",
          "chgp": "-16.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "205.60%",
          "val2": "240.90%",
          "chgp": "-3.53%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
766.20
698.20
9.74%
Operating Profit (PBDIT) excl Other Income
199.60
168.40
18.53%
Interest
0.10
0.40
-75.00%
Exceptional Items
-3.10
-19.70
84.26%
Consolidate Net Profit
131.80
89.80
46.77%
Operating Profit Margin (Excl OI)
206.50%
183.90%
2.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.74% vs -6.72% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 46.77% vs -30.98% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,892.70
2,951.10
-1.98%
Operating Profit (PBDIT) excl Other Income
750.00
848.20
-11.58%
Interest
2.90
8.80
-67.05%
Exceptional Items
-19.00
-13.80
-37.68%
Consolidate Net Profit
492.70
593.40
-16.97%
Operating Profit Margin (Excl OI)
205.60%
240.90%
-3.53%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -1.98% vs 2.27% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -16.97% vs 1.28% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About West Pharmaceutical Services, Inc. stock-summary
stock-summary
West Pharmaceutical Services, Inc.
Pharmaceuticals & Biotechnology
West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.
Company Coordinates stock-summary
Company Details
530 HERMAN O WEST DR , EXTON PA : 19341-1147
stock-summary
Tel: 1 610 59429001 610 5943318
stock-summary
https://www.westpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."